Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
Open Access
- 28 January 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (10) , 4568-4580
Abstract
Objectives: To determine s.c. tocilizumab (s.c.-TCZ) dosing regimens for systemic JIA (sJIA) and polyarticular JIA (pJIA). Methods: In two 52-week phase 1 b trials, s.c.-TCZ (162 mg/dose) was administered to sJIA patients every week or every 2 weeks (every 10 days before interim analysis) and to pJIA patients every 2 weeks or every 3 weeks with body weight ≥30 kg or 5th percentile of that achieved with i.v.-TCZ was achieved by 49 (96%) sJIA and 52 (100%) pJIA patients. In both populations, pharmacodynamic markers of disease were similar between body weight groups. Improvements in Juvenile Arthritis DAS-71 were comparable between s.c.-TCZ and i.v.-TCZ. By week 52, 53% of sJIA patients and 31% of pJIA patients achieved clinical remission on treatment. Safety was consistent with that of i.v.-TCZ except for injection site reactions, reported by 41.2% and 28.8% of sJIA and pJIA patients, respectively. Infections were reported in 78.4% and 69.2% of patients, respectively. Two sJIA patients died; both deaths were considered to be related to TCZ. Conclusion: s.c.-TCZ provides exposure and risk/benefit profiles similar to those of i.v.-TCZ. S.c. administration provides an alternative administration route that is more convenient for patients and caregivers and that has potential for in-home use. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT01904292 and NCT01904279Keywords
Funding Information
- sponsor, Roche. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd
This publication has 38 references indexed in Scilit:
- Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic ArthritisNew England Journal of Medicine, 2012
- Clarification on Precision Criteria to Derive Sample Size When Designing Pediatric Pharmacokinetic StudiesThe Journal of Clinical Pharmacology, 2012
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6International Journal of Biological Sciences, 2012
- American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritisArthritis Care & Research, 2011
- Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)Archives of Disease in Childhood, 2011
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Treatment choices, preferences and decision‐making by patients with rheumatoid arthritisMusculoskeletal Care, 2007
- Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypesArthritis & Rheumatism, 1995
- Correlation of Serum Interleukin‐6 Levels with Joint Involvement and Thrombocytosis in Systemic Juvenile Rheumatoid ArthritisArthritis & Rheumatism, 1991